The risk for disease progression, thrombosis, and mortality in essential thrombocythemia can be predicted with “readily available” patient information.
Matched sibling donors aside, donor type was not associated with significant differences in overall survival in patients with myelofibrosis who underwent hematopoietic cell transplantation (HCT), according to study results...
Risk factors for bleeding and thrombosis among patients with myeloproliferative neoplasms (MPNs) who are scheduled for surgery are multifaceted and require consideration of individual patient characteristics, risk assessment,...